Maxigen Biotech Inc.
1783
Rank in Stocks
#19726
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development,... Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
Share Price
$1.09
Last synced: 2026-11-13
Market Cap
$98.01M
Change (1 day)
0.36%
Change (1 year)
-23.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Maxigen Biotech Inc. (1783)
Category
Healthcare
Operating Margin for Maxigen Biotech Inc. (1783)
Operating Margin as of November 2026 TTM: 32.83%
According to Maxigen Biotech Inc.'s latest financial reports, its current operating margin (TTM) is 32.83%. At the end of 2025 the company had an operating margin of 32.17%.
Operating Margin history for Maxigen Biotech Inc. from 2009 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 32.83% | 2.05% |
| 2025 | 32.17% | 12.64% |
| 2024 | 28.56% | 18.56% |
| 2023 | 24.09% | -14.64% |
| 2022 | 28.22% | 43.47% |
| 2021 | 19.67% | 17.08% |
| 2020 | 16.80% | -0.18% |
| 2019 | 16.83% | 55.98% |
| 2018 | 10.79% | 119.31% |
| 2017 | 4.92% | -246.43% |
| 2016 | -3.36% | -85.49% |
| 2015 | -23.15% | 98.88% |
| 2014 | -11.64% | 660.78% |
| 2013 | -1.53% | -68.19% |
| 2012 | -4.81% | -79.34% |
| 2011 | -23.28% | 29.77% |
| 2010 | -17.94% | -542.96% |
| 2009 | 4.05% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 28.37% | -99.14% |
US
|
|
| 12.36% | -99.62% |
FR
|
|
| 11.78% | -99.64% |
US
|
|
| 31.11% | -99.05% |
JP
|
|
| 10.21% | -99.69% |
CH
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Maxigen Biotech Inc.'s operating margin
What is Maxigen Biotech Inc.'s operating margin?
Maxigen Biotech Inc.'s operating margin is 32.83%, as of Nov 2026.
What was Maxigen Biotech Inc.'s operating margin in 2025?
In 2025, Maxigen Biotech Inc.'s operating margin was 32.17%, compared with 28.56% in 2024.
How has Maxigen Biotech Inc.'s operating margin changed since 2020?
From 2020 to 2025, Maxigen Biotech Inc.'s operating margin was highest in 2025 (32.17%) and lowest in 2020 (16.80%).
How does Maxigen Biotech Inc.'s operating margin compare with similar companies?
Maxigen Biotech Inc.'s operating margin (32.83%) is higher than that of all 5 similar companies listed above. The highest among them is HOYA Corporation, with 31.11%.